LNTH · XBRL financial data

Lantheus Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LNTH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	320	354*	370	394	379	391*	373	378	384	407*	377	388
Cost of goods and services sold	120	124*	128	138	137	143*	135	137	162	166*	146	146
Gross profit	200	230*	242	256	242	249*	238	241	222	241*	231	242
Research and development	14	17*	48	61	24	35*	36	45	48	47*	39	38
General and administrative	36	40*	48	47	41	58*	57	67	82	70*	58	21
Operating income (loss)	112	137*	107	103	134	114*	102	88	44	77*	81	100
Interest income	—	year only	—	—	—	year only	—	—	—	—	—	—
Interest expense	5	5*	5	5	5	5*	5	5	5	5*	5	5
Other income (expense)	53	6*	9	9	10	9*	14	7	3	8*	6	8
Income tax expense (benefit)	28	35*	40	22	45	11*	24	26	15	16*	38	19
Net income (loss)	132	103*	131	62	131	(12)*	73	79	28	54*	118	75
Earnings per share, basic USD per share	1.93	1.51*	1.91	0.89	1.89	(0.17)*	1.06	1.15	0.41	0.82*	1.83	1.15
Earnings per share, diluted USD per share	1.88	1.43*	1.87	0.88	1.79	(0.16)*	1.02	1.12	0.41	0.84*	1.80	1.11
Weighted average shares, basic millions of shares	68	68*	69	69	69	69*	69	69	67	66*	65	65
Weighted average shares, diluted millions of shares	70	72*	70	71	73	73*	71	70	68	64*	66	68

Fiscal quarters (LNTH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	614	714	718	757	866	913	939	696	382	359	499	593
Accounts receivable	259	284	337	372	329	321	349	337	351	359	356	353
Inventory	56	64	70	71	71	68	69	62	62	65	61	58
Total current assets	948	1,086	1,149	1,231	1,296	1,327	1,424	1,202	925	900	942	1,027
Property and equipment, net	140	147	150	158	170	177	181	158	164	164	158	153
Right-of-use asset	46	45	44	43	39	36	—	—	—	31	—	—
Goodwill	61	61	61	61	61	61	61	177	240	240	239	239
Total assets	1,522	1,651	1,831	1,940	2,050	1,980	2,055	2,116	2,276	2,227	2,347	2,415
Accounts payable	37	41	38	50	45	35	45	41	66	43	46	48
Current portion of long-term debt	1	1	1	1	565	1	1	1	1	1	1	1
Total current liabilities	177	187	237	263	784	241	248	280	347	333	333	336
Lease liability, non-current	54	54	54	54	54	53	48	48	51	50	55	54
Total liabilities	823	835	886	913	870	892	891	949	1,157	1,138	1,134	1,103
Retained earnings	30	134	265	327	458	446	519	598	625	680	798	873
Total stockholders' equity	699	816	946	1,027	1,180	1,088	1,164	1,167	1,119	1,090	1,212	1,312
Total liabilities and equity	1,522	1,651	1,831	1,940	2,050	1,980	2,055	2,116	2,276	2,227	2,347	2,415
Common shares outstanding (cover page) millions of shares	68	69	69	69	70	68	69	68	66	65	65	65

Fiscal quarters (LNTH's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	132	103*	131	62	131	(12)*	73	79	28	54*	118	75
Stock-based compensation	14	14*	15	18*	20*	22*	21	22*	25*	18*	16	20*
Net cash from operating activities	117*	112*	127	85*	175*	158*	108	87*	105*	90*	125	92*
Net cash from investing activities	83*	(12)*	(107)	(45)*	(68)*	(7)*	(64)	(232)*	(319)*	(12)*	26	(2)*
Proceeds from issuing common stock	1*	0*	2	0*	2*	0*	2	—	—	—	0	—
Share repurchases	—	year only	—	—	0*	100*	—	—	100*	100*	—	—
Proceeds from long-term debt	—	year only	—	—	—	year only	—	—	—	—	—	—
Repayments of long-term debt	0*	0*	0	0*	(0)*	(0)*	0	0*	0*	0*	0	0*
Net cash from financing activities	0*	(0)*	(17)	0*	2*	(104)*	(18)	(98)*	(99)*	(101)*	(12)	5*
Net change in cash	200*	100*	5	39*	109*	46*	26	(243)*	(314)*	(23)*	139	95*

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026

Not investment advice. Not affiliated with the U.S. SEC.